Canephron N

Canephron N (also known as CLR, BNO 1045, or BNO 2103) is an orally bioavailable herbal medicinal product developed by Bionorica SE. It consists of a standardized 1:1:1 mixture of pulverized centaury herb (Centaurium erythraea), lovage root (Levisticum officinale), and rosemary leaves (Rosmarinus officinalis). Canephron N is approved in numerous countries for the treatment and supportive management of acute uncomplicated lower urinary tract infections (uUTIs), such as cystitis, as well as chronic kidney diseases like pyelonephritis and glomerulonephritis. It exerts multi-target pharmacological effects, including anti-inflammatory, spasmolytic, antinociceptive, diuretic, and anti-adhesive activities. In a Phase 3 non-inferiority trial (NCT02639520), Canephron N demonstrated non-inferiority to the antibiotic fosfomycin trometamol in reducing the need for additional antibiotic treatment in women with acute uncomplicated cystitis, while preserving the gut microbiome. Its molecular mechanisms include the suppression of NF-κB activation, inhibition of ALOX5 and PTGES (mPGES-1) pathways, and modulation of the p38 MAPK-MK2 and RIPK1 signaling cascades.

Brand names

Canephron NCanephronCanephron UNO

Other names

CLRCentaury, Lovage root, Rosemary leaf combination